April, 2015 (ASNTR Special Issue)

Cell Transplantation

The Regenerative Medicine Journal

Studies in cell transplantation show beneficial effects for variety of serious conditions

American Society for Neural Therapy and Repair members further cell transplantation efforts

Putnam Valley, NY. (April, 2015) – Five studies from a special issue of  Cell Transplantation devoted to work presented at a recent meeting of the American Society for Neural Therapy and Repair (ASNTR), a society for scientists society focused on cell therapy, stem cells, gene therapy and biopharmaceuticals for neurological injury and disease, are currently freely available on-line e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-CT-1239_Tabakow_et_al

MSCs promote improvement in patient with complete spinal cord injury

Complete spinal cord injury (SCI) leads to profound disability and, with long-term complications, even death. This study demonstrated the potential of transplanted bone marrow nucleated cells (BMNCs) to restore feeling and function to the lower body. Over a two year period, researchers assessed the safety and efficacy of combined intravenous/intrathecal autologous (other donated) BMNCs and multiple  lumbar puncture  mensenchymal cells (MSCs) in treating a patient with complete SCI. Results suggested that the treatment had the potential to produce “clinically meaningful improvements for SCI patients” as this patient experienced a restored ability to control his body trunk, a restoration of bladder and anal sensation, and gained the ability to stand with a standing frame and walk with the support of hip and knee ortheses.

#

Contact: Dr. Marcin Majka, Department of Transplantation, Polish-American Institute of Pediatrics, Jagiellonian University, Wielicka St. 265, 30-663 Cracow, Poland. Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it Fax: +48-12-659-1594 Ph: +48-12-659-1593 Citation: xxxxxxxxxxxxxxxx. Cell Transplant. Appeared or available on-line: xxxxxxx.

##

Bone marrow MSC culture enhances human neural stem cells

“Rapid loss of stemness capacity in purified prototype neural stem cells (NSCs) remains a serious challenge to basic and clinical studies aimed at repairing the central nervous system,” wrote a team of researchers from the Harvard Medical School and the Boston Veteran’s Administration Health System.  The researchers tested human NSCs and human mensenchymal cells (MSCs) to find out if bone marrow-derived MSCs could enhance the “stemness” of human NSCs. They speculated that the a biological pathway called Notch-1might be a major mechanism through which hNSCs and hMSCs communicate to ‘modulate’ their stemness biology through direct interactions, offering a potential strategy for hNCS stemness enhancement.

After their experiments in co-culturing hNSCs and hMSCs they found that enhancement of the stemness of hNSCs occurred through Notch-1 signaling.

“Our finding provides mechanistic leads for devising effective regimens to sustain and augment stemness of in vitro established hNSC and hMSC lines for use in basic science as well as translational and clinical applications,” concluded the researchers.

#

Contact: Dr. Yang D. Teng Email:  This e-mail address is being protected from spambots. You need JavaScript enabled to view it Citation: xxxxxxxxxxxxxxxx. Cell Transplant. Appeared or available on-line: xxxxxxx.

##

Primate model of Parkinson’s disease study shows role for upgrading endogenous neurons

The possibilities for having the brain help heal itself when afflicted by neurological disorders such as Parkinson’s disease (PD) is an area of interest. In this study, researchers observed primates modeled with PD and assessed changes in the numbers of neurons expressing the enzyme tyrosine hydroxylase (TH), a precursor for dopamine.  They discovered “a close relationship” between PD symptom severity and striatal DA neuron numbers. The possibility of increasing the numbers of these neurons as compensation for their depletion in PD by artificial means “could prove beneficial for PD treatment, especially for individuals in the early disease stages,” they concluded.

#

Contact: Dr. Andrew.Bubank, University of Colorado-Denver, Department of Integrative Biology, Campus Box 171 POB 17336, Denver, CO 80217-3364 Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it Ph: 605-481-0349 Citation: xxxxxxxxxxxxxxxx. Cell Transplant. Appeared or available on-line: xxxxxxx2015.

##

Human pluripotent stem cells hold promise for Parkinson’s disease

Recent studies have shown that human pluripotent stem cells (PSCs) may hold promise for treating Parkinson’s disease (PD).  Transplanted fetal neural tissue has been shown to provide improvements in PD, but the source of this tissue is limited and controversial. Looking for alternatives and proof of concept, the researchers studied the benefits of using human pluripotent stem cells (hPSCs) and neural stem cells (NSCs) to engraft into animal models of PD.

“In this study we showed for the first time the successful engraftment and safety of human parthenogenetic stem cells derived from NSCs following transplantation in rodent and non-human primate PD models,” concluded the researchers. “In both models, transplantation of hpNSCs led to improvement of DA (dopamine) levels, which could be explained by the multimodal actions of the NSCs, to include neuroprotection and cell replacement.”

#

Contact: Dr. Ruslan Semechkin, International Stem cell Corporation, 5950 Priestly Dr. Carlsbad, CA 92008, USA Email:  This e-mail address is being protected from spambots. You need JavaScript enabled to view it Citation: xxxxxxxxxxxxxxxx. Cell Transplant. Appeared or available on-line: xxxxxxxxxxxxxx 2015..

Anti-tumor effect of secreted factors studied for effect on glioblastoma-like cells

Researchers studied the possible anti-tumor effects of the secreted factors from mensenchymal stem cells (MSCs) on four glioblastoma stem-like cells (GSLC) and found that MSCs “have an intrinsic ability to inhibit cell cycle, induce senescence (halt cell division) and prevent differentiation of GSLCs.”

“Glioblastoma multiform (GBM) is the most malignant type of brain tumor that is still incurable, due to its characteristic highly infiltrative growth and resistance to therapy,” said the researchers. “The highly tumorigenic subpopulation of cells with stem cell-like properties are presumably the cause for GBM recurrence.”

The researchers hypothesized that the secreted factors from the MSCs could cause an alteration in the GLSCs’ behavior and did in fact observe that they cause cell cycle arrest. They also found that the MSCs also increased the sensitivity of GSLCs to chemotherapy.

#

Contact: Dr. Helena Motain, National Institute of Biology, Department of Genetic Toxicology and Cancer Biology, Venca pot 111, SL-1000 Ljubljana, Slovenia. Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it Ph: + 386 5923 2870 Citation: xxxxxxxxxxxxxxxx. Cell Transplant. Appeared or available on-line: xxxxxxxxxxxxx 2015.

##

The Coeditors-in-chief for CELL TRANSPLANTATION are at the Diabetes Research Institute, University of Miami Miller School of Medicine and Center for Neuropsychiatry, China Medical University Hospital, TaiChung, Taiwan. Contact, Camillo Ricordi, MD at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or Shinn-Zong Lin, MD, PhD at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or David Eve, PhD or Samantha Portis, MS, at This e-mail address is being protected from spambots. You need JavaScript enabled to view it

News release by Florida Science Communications www.sciencescribe.net

Return to Press Releases>